These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25998042)

  • 1. Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
    Singh RP; Patel B; Kallender H; Ottesen LH; Adams LM; Cox DS
    J Clin Pharmacol; 2015 Oct; 55(10):1184-92. PubMed ID: 25998042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
    Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
    Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H; Ong R; Soo KC
    Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
    Yau TCC; Lencioni R; Sukeepaisarnjaroen W; Chao Y; Yen CJ; Lausoontornsiri W; Chen PJ; Sanpajit T; Camp A; Cox DS; Gagnon RC; Liu Y; Raffensperger KE; Kulkarni DA; Kallender H; Ottesen LH; Poon RTP; Bottaro DP
    Clin Cancer Res; 2017 May; 23(10):2405-2413. PubMed ID: 27821605
    [No Abstract]   [Full Text] [Related]  

  • 7. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
    Hsyu PH; Mould DR; Abbas R; Amantea M
    Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
    Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
    Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
    Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.
    Lacy S; Yang B; Nielsen J; Miles D; Nguyen L; Hutmacher M
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1071-1082. PubMed ID: 29687244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
    Shah MA; Wainberg ZA; Catenacci DV; Hochster HS; Ford J; Kunz P; Lee FC; Kallender H; Cecchi F; Rabe DC; Keer H; Martin AM; Liu Y; Gagnon R; Bonate P; Liu L; Gilmer T; Bottaro DP
    PLoS One; 2013; 8(3):e54014. PubMed ID: 23516391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
    Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
    Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
    Okusaka T; Aramaki T; Inaba Y; Nakamura S; Morimoto M; Moriguchi M; Sato T; Ikawa Y; Ikeda M; Furuse J
    Cancer Sci; 2015 May; 106(5):611-7. PubMed ID: 25711511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.